NL-OMON54559招募中不适用
Diagnostic tool to safely CEASE anti-TNF therapy in Crohn*s disease: a center-specific, stepped wedge Randomized Controlled Trial - CEASE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 252
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 至 99（—）
入选标准
- •- Luminal CD as indication for anti-TNF therapy
- •- Clinical remission (HBI < 5)
- •- Duration of anti-TNF treatment >= 12 months and a stable dose >= 3 months
- •- Relapse risk < 33.3% after cessation of anti-TNF as predicted by the
- •diagnostic tool (*low risk*)
排除标准
- •- Ulcerative colitis or IBD-unclassified.
- •- Co-morbidities that are a contraindication for (dis)continuing anti-TNF
- •therapy (such as rheumatic diseases or perianal fistula)
- •- Corticosteroid use 6 months prior to inclusion
- •- Malignancy (< 5 years prior to start of the study)
- •- Pregnancy
研究者
相似试验
尚未招募
不适用
A Prediction Model to Safely CEASE Anti-TNF Therapy in Patients with Crohn's DiseaseCrohn's DiseaseNL-OMON25895Amsterdam UMC, location AMC and Erasmus MC190
进行中（未招募）
1 期
Anti-TNF discontinuation in patients with inflammatory bowel diseaseInflammatory bowel diseaseMedDRA version: 19.0Level: LLTClassification code 10021973Term: Inflammatory bowel disease NOSSystem Organ Class: 100000004856EUCTR2015-001410-10-ESFundación de Investigación Biomédica Hospital Universitario de la Princesa300
已完成
不适用
Anti-TNF-Study Utilizing Biomarker Assay to Monitor Early Response to Certolizumab PegolRheumatoid ArthritisJPRN-UMIN000022831niversity of Occupational and Environmental Health, Japan100
进行中（未招募）
1 期
Biomarkers identification of efficacy in Ankylosing SpondylitisAnkylosing SpondylitisEUCTR2013-004406-25-PTFaculdade de Ciências Médicas da Universidade Nova de Lisboa70
已完成
不适用
Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?Colitis,UlcerativeNCT03011268Helse Møre og Romsdal HF174